Mainz Biomed N.V. (MYNZ)

0.7500 -0.1300 (-14.77%) At close: 04:00PM EDT

Mainz Biomed N.V.

Robert Koch Strasse 50
Mainz 55129
Germany
49 6131 554 2860
https://mainzbiomed.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 65

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Guido Baechler	CEO & Executive Director	N/A	N/A	1965
Mr. William J. Caragol	Chief Financial Officer	N/A	N/A	1967
Dr. Christopher Von Torne P.M.P., Ph.D.	Chief Operating Officer	N/A	N/A	1972
Dr. Frank Krieg-Schneider	Chief Technology Officer	N/A	N/A	1962
Dr. Moritz Eidens Ph.D.	Chief Science Officer & Executive Director	N/A	N/A	1984
Stefan Erlach	Head of Human Resources	N/A	N/A	N/A
Mr. Philipp Freese	Chief Business Officer	N/A	N/A	1983
Mr. Darin S. Leigh	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

Corporate governance

Mainz Biomed N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.